Citation Impact
Citing Papers
Cardiac Hypertrophy: The Good, the Bad, and the Ugly
2003 Standout
Recent Advances in <I>Ο</I>- Glycosylation
1983
The re-emergence of natural products for drug discovery in the genomics era
2015 Standout
Gold Catalysis
2006 Standout
Targeting hypoxia in cancer therapy
2011 Standout
Effects of Fibrates on Metabolism of Statins in Human Hepatocytes
2002
Hypervalent iodine reagents as a new entrance to organocatalysts
2009 Standout
The Effect of Converting from Pravastatin to Simvastatin on the Pharmacodynamics of Warfarin
1999
Polymorphism of human cytochrome P450 enzymes and its clinical impact
2009
Human Liver Expression of CYP2C8: Gender, Age, and Genotype Effects
2010
Clinical pharmacology of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors
1999
HMG-CoA reductase activity in human liver microsomes: comparative inhibition by statins
2000
Disulfonimide‐Catalyzed Asymmetric Vinylogous and Bisvinylogous Mukaiyama Aldol Reactions
2010 StandoutNobel
Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin
1999
Vascular endothelial growth factor in eye disease
2008 Standout
A survey of yeast genomic assays for drug and target discovery
2010
Mechanisms of drug combinations: interaction and network perspectives
2009 Standout
The chemistry and biotransformation of tea constituents
2011
‘Fire and forget?’ — pharmacological considerations in coronary care
1999
Statin-Associated Myopathy with Normal Creatine Kinase Levels
2002 Standout
Inflammation in atherosclerosis
2002 StandoutNature
Systematic Overview of Warfarin and Its Drug and Food Interactions
2005 Standout
Involvement of human cytochromes P450 (CYP) in the reductive metabolism of AQ4N, a hypoxia activated anthraquinone DI-N-oxide prodrug
1998
Effect of cerivastatin sodium, a new inhibitor of HMG‐CoA reductase, on plasma lipid levels, progression of atherosclerosis, and the lesional composition in the plaques of WHHL rabbits
1999
Metabolism and Drug Interactions of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors in Transplant Patients
1998
A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness
2010 Standout
Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation
2013 Standout
Comparative pharmacology of rosuvastatin
2003
Statins lower plasma and lymphocyte ubiquinol/ubiquinone without affecting other antioxidants and PUFA
2003
Monofluorination of Organic Compounds: 10 Years of Innovation
2015 Standout
Iron Catalysis in Organic Synthesis
2015 Standout
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Data-Mining for Sulfur and Fluorine: An Evaluation of Pharmaceuticals To Reveal Opportunities for Drug Design and Discovery
2013 Standout
Analysis of the Structural Diversity, Substitution Patterns, and Frequency of Nitrogen Heterocycles among U.S. FDA Approved Pharmaceuticals
2014 Standout
Glycosylation using glucopyranosyl fluorides and silicon-based catalysts. Solvent dependency of the stereoselection
1984 StandoutNobel
Amelioration of Angiotensin II–Induced Cardiac Injury by a 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor
2001
Stereoselective synthesis of α-glucosides from 3-O-propargyl protected glucal exploiting the alkynophilicity of AuCl3
2006
Inflammation in Atherosclerosis
2012 Standout
Statins Have Biphasic Effects on Angiogenesis
2002
The Many Roles for Fluorine in Medicinal Chemistry
2008 Standout
Safety and Toxicology of Magnolol and Honokiol
2018 Standout
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Disulfonimid‐katalysierte asymmetrische vinyloge und bisvinyloge Mukaiyama‐Aldolreaktionen
2010 StandoutNobel
Development and Applications of Disulfonimides in Enantioselective Organocatalysis
2015 StandoutNobel
PLEIOTROPIC EFFECTS OF STATINS
2004 Standout
III Diretrizes Brasileiras Sobre Dislipidemias e Diretriz de Prevenção da Aterosclerose do Departamento de Aterosclerose da Sociedade Brasileira de Cardiologia
2001 Standout
Fluorine in Pharmaceuticals: Looking Beyond Intuition
2007 StandoutScience
Inflammation and Atherosclerosis
2002 Standout
The Reciprocal Interactions between Polyphenols and Gut Microbiota and Effects on Bioaccessibility
2016 Standout
Organic Polyvalent Iodine Compounds
1996 Standout
An HMG-CoA Reductase Inhibitor, Cerivastatin, Suppresses Growth of Macrophages Expressing Matrix Metalloproteinases and Tissue Factor In Vivo and In Vitro
2001
Apparent Catalytic Generation of Chiral Metal Enolates: Enantioselective Dienolate Additions to Aldehydes Mediated by Tol-BINAP·Cu(II) Fluoride Complexes
1998
Fluorine in medicinal chemistry: Recent therapeutic applications of fluorinated small molecules
2006 Standout
Pharmacogenetic testing among patients with mood and anxiety disorders is associated with decreased utilization and cost: A propensity-score matched study
2018 StandoutNobel
Scope of AuCl3 in the activation of per-O-acetylglycals
2009
Hypervalent iodine in organic synthesis
1986
Gold-Catalyzed Carbon−Heteroatom Bond-Forming Reactions
2011 Standout
Treatment of Relapsing Paralysis in Experimental Encephalomyelitis by Targeting Th1 Cells through Atorvastatin
2003
Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
2004 Standout
Gold-Catalyzed Organic Reactions
2007 Standout
The Vinylogous Aldol Reaction: A Valuable, Yet Understated Carbon−Carbon Bond-Forming Maneuver
2000 Standout
Ferric sulfate hydrate-catalyzed O-glycosylation using glycals with or without microwave irradiation
2007
Fluorination in Medicinal Chemistry: Methods, Strategies, and Recent Developments
2008 Standout
Works of Rolf Angerbauer being referenced
Preclinical review of cerivastatin sodium—a step forward in HMG-CoA reductase inhibition
1998
Cerivastatin: pharmacology of a novel synthetic and highly active HMG-CoA reductase inhibitor
1997
Synthesis and glycosidation reactions of acetylated racemic pseudoglycals1
1981
A convenient preparation of 2,3-unsaturated N-galactosyl derivatives
1979
Metabolism of cerivastatin by human liver microsomes in vitro. Characterization of primary metabolic pathways and of cytochrome P450 isozymes involved.
1997
93 Cerivastatin: High enzyme affinity and active metabolites contribute to its high pharmacological activity
1997
BAY W 6228
1994
Biotransformation of cerivastatin in mice, rats, and dogs in vivo.
1998
Einfache de‐novo‐Synthese reaktiver Pseudoglykale (Hex‐2‐enopyranoside) – stereospezifische α‐Glykosid‐verknüpfung
1977
Simple de‐novo Synthesis of Reactive Pseudoglycals (Hex‐2‐enopyranosides)—Stereospecific α‐Glycoside Coupling
1977